MD, University of Genoa
Residency, University of Genoa
, Neuroimaging Research Unit, San Raffaele Hospital
, New York University, Radiology Department
PhD, University of Genoa
Novel MRI Markers of Progressive Multiple Sclerosis
Recent brain pathology studies have shown that patients with progressive MS present a pattern of extensive cortical demyelination and more diffuse injury of normal-appearing white matter. Using novel MRI techniques such as double inversion recovery, diffusional kurtosis and perfusion imaging, we are measuring cortical lesions and microstructural and metabolic gray matter injury in patients with primary progressive MS. Also, we are investigating the role of gray matter injury in development of brain atrophy and cognitive deficits.
Non-invasive Brain Sodium Quantification in Multiple Sclerosis
It has been suggested that the accumulation of intra-axonal sodium represents a key factor in the degenerative process of MS. Changes in tissue sodium concentration can be measured in vivo by single quantum Sodium MR Imaging. The application of triple quantum sodium filtration, allows the measurement of intracellular sodium concentration. Using ultra-high field MRI (7T) in collaboration with the Center for Biomedical Imaging at NYU we are investigating whether sodium-related brain tissue damage is critical for the accumulation of clinical disability in MS
Inglese M, Ge Y, Filippi M, Falini A, Grossman RI, Gonen O. Indirect evidence for early widespread gray matter involvement in relapsing-remitting multiple sclerosis. NeuroImage 2004 Apr; 21(4).
Inglese M, Liu S, Babb JS, Mannon LJ, Grossman RI, Gonen O. Three-dimensional proton spectroscopy of deep gray matter nuclei in relapsing-remitting MS. Neurology 2004 Jul; 63(1).
Filippi M, Rovaris M, Inglese M, Barkhof F, De Stefano N, Smith S, Comi G. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet; 364(9444).
Adhya S, Johnson G, Herbert J, Jaggi H, Babb JS, Grossman RI, Inglese M. Pattern of hemodynamic impairment in multiple sclerosis: dynamic susceptibility contrast perfusion MR imaging at 3.0 T. NeuroImage 2006 Dec; 33(4).
Inglese M, Park SJ, Johnson G, Babb JS, Miles L, Jaggi H, Herbert J, Grossman RI. Deep gray matter perfusion in multiple sclerosis: dynamic susceptibility contrast perfusion magnetic resonance imaging at 3 T. Archives of neurology 2007 Feb; 64(2).
Inglese M, Adhya S, Johnson G, Babb JS, Miles L, Jaggi H, Herbert J, Grossman RI. Perfusion magnetic resonance imaging correlates of neuropsychological impairment in multiple sclerosis. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2008 Jan; 28(1).
Inglese M, Rusinek H, George IC, Babb JS, Grossman RI, Gonen O. Global average gray and white matter N-acetylaspartate concentration in the human brain. NeuroImage 2008 Jun; 41(2).
Bakshi R, Thompson AJ, Rocca MA, Pelletier D, Dousset V, Barkhof F, Inglese M, Guttmann CR, Horsfield MA, Filippi M. MRI in multiple sclerosis: current status and future prospects. Lancet neurology 2008 Jul; 7(7).
Inglese M, Madelin G, Oesingmann N, Babb JS, Wu W, Stoeckel B, Herbert J, Johnson G. Brain tissue sodium concentration in multiple sclerosis: a sodium imaging study at 3 tesla. Brain : a journal of neurology 2010 Mar; 133(Pt 3).
Fleysher L, Oesingmann N, Inglese M. B₀ inhomogeneity-insensitive triple-quantum-filtered sodium imaging using a 12-step phase-cycling scheme. NMR in biomedicine 2010 Dec; 23(10).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Inglese did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.